OptimizeRx (NASDAQ:OPRX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

OptimizeRx (NASDAQ:OPRX) released its earnings results on Tuesday. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13, FiscalAI reports. The firm had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.35 million. OptimizeRx had a net margin of 4.69% and a return on equity of 10.61%.

OptimizeRx Price Performance

Shares of OPRX traded up $0.13 during trading hours on Tuesday, hitting $6.34. The stock had a trading volume of 597,335 shares, compared to its average volume of 436,489. The company’s fifty day moving average is $6.61 and its two-hundred day moving average is $11.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.04 and a quick ratio of 3.04. OptimizeRx has a 52 week low of $5.54 and a 52 week high of $22.25. The stock has a market capitalization of $118.94 million, a price-to-earnings ratio of 24.39 and a beta of 1.19.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Lake Street Capital cut their target price on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. B. Riley Financial restated a “buy” rating and issued a $11.00 price objective (down from $28.00) on shares of OptimizeRx in a research note on Friday, March 6th. Stifel Nicolaus dropped their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Finally, Roth Mkm dropped their price objective on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently added to or reduced their stakes in OPRX. Manatuck Hill Partners LLC grew its holdings in OptimizeRx by 139.5% during the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock worth $6,142,000 after acquiring an additional 265,000 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in OptimizeRx by 42.8% during the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after acquiring an additional 202,446 shares during the last quarter. Invesco Ltd. bought a new stake in OptimizeRx during the 3rd quarter worth about $4,081,000. Harvest Investment Services LLC bought a new stake in OptimizeRx during the 3rd quarter worth about $3,441,000. Finally, Balyasny Asset Management L.P. bought a new stake in OptimizeRx during the 2nd quarter worth about $2,111,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx announced that its board has authorized a stock buyback program on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.